References
- Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359–86. doi:https://doi.org/10.1002/ijc.29210
- Chen VW, Ruiz BA, Hsieh MC, et al. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 2014;120:3781–3792.
- Bruni A, Giaj-Levra N, Ciammella P, et al. Management of locally advanced non-small cell lung cancer in the modern era: a national Italian survey on diagnosis, treatment and multidisciplinary approach. PLoS One. 2019 Nov 13 14:(11) e0224027. https://doi.org/10.1371/journal.pone.0224027. *A national vision of the unmet needs on unresectable stage III NSCLC by the Radiation Oncology Italian Society
- Langer CJ, Hsu C, Curran WJ, et al. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of radiation therapy oncology group (RTOG) 94-10. J Clin Oncol. 2002; 21 (Proceedings of the American Society of Clinical Oncology): A–1193
- Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181–2190. doi:https://doi.org/10.1200/JCO.2009.26.2543
- Antonia SJ, Villegas A, Daniel D, et al. durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017 Nov 16 377:(20) 1919–1929. https://doi.org/10.1056/NEJMoa1709937. **The standard treatment of the unresectable stage III NSCLC
- Schulkes KJ, Hamaker ME, van den Bos F, et al. Relevance of a geriatric assessment for elderly patients with lung cancer-a systematic review. Clin Lung Cancer. 2016 Sep;17(5):341–349.e3. DOI:https://doi.org/10.1016/j.cllc.2016.05.007.
- De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009 Jan;20(1):98–102. DOI:https://doi.org/10.1093/annonc/mdn559.
- Nestle U, De Ruysscher D, Ricardi U, et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018 Apr;127(1):1–5. DOI:https://doi.org/10.1016/j.radonc.2018.02.023.
- De Ruysscher D, Faivre-Finn C, Nackaerts K, et al. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Ann Oncol. 2020 Jan;31(1):41–49. DOI:https://doi.org/10.1016/j.annonc.2019.10.003.
- Merlotti A, Bruni A, Borghetti P, et al. Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian association of radiotherapy and clinical oncology (AIRO). Radiol Med. 2021 Aug;126(8):1117–1128. DOI:https://doi.org/10.1007/s11547-021-01362-8.
- Franceschini D, Bruni A, Borghetti P, et al. Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. Radiol Med. 2020 Feb;125(2):214–219. DOI:https://doi.org/10.1007/s11547-019-01094-w.
- Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):444–450. doi:https://doi.org/10.1016/j.ijrobp.2012.04.043
- Giuranno L, Ient J, De Ruysscher D, et al. Radiation-Induced Lung Injury (RILI). Front Oncol. 2019 Sep 6;9:877.https://doi.org/10.3389/fonc.2019.00877.
- De Ruysscher D, Dehing C, Yu S, et al. Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol. 2009;91:353–359.
- Grambozov B, Wolf F, Kaiser J, et al. Pulmonary function decreases moderately after accelerated high-dose irradiation for stage III non-small cell lung cancer. Thorac Cancer. 2020 Feb;11(2):369–378. DOI:https://doi.org/10.1111/1759-7714.13276.
- Niezink AGH, de Jong RA, Muijs CT, et al. Pulmonary function changes after radiotherapy for lung or esophageal cancer: a systematic review focusing on dose-volume parameters. Oncologist. 2017 Oct;22(10):1257–1264. DOI:https://doi.org/10.1634/theoncologist.2016-0324.
- Shin S, Choi YS, Jung JJ, et al. Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. Respir Res. 2020 Jan 10;21(1):13. doi:https://doi.org/10.1186/s12931-019-1254-0
- Vekens K, Verbanck S, Collen C, et al. Pulmonary function changes following helical tomotherapy in patients with inoperable, locally advanced non-small cell lung cancer. Strahlenther Onkol. 2020 Feb;196(2):142–150. DOI:https://doi.org/10.1007/s00066-019-01489-8.
- Schröder C, Buchali A, Windisch P, et al. Impact of Low-dose irradiation of the lung and heart on toxicity and pulmonary function parameters after thoracic radiotherapy. Cancers (Basel). 2020 Dec 23;13(1):22. doi:https://doi.org/10.3390/cancers13010022
- Lopez Guerra JL, Gomez DR, Zhuang Y, et al. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e537–43. doi:https://doi.org/10.1016/j.ijrobp.2012.01.019
- Torre-Bouscoulet L, Muñoz-Montaño WR, Martínez-Briseño D, et al. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer. Respir Res. 2018 Apr 24;19(1):72. doi:https://doi.org/10.1186/s12931-018-0775-2
- Stone B, Mangona VS, Johnson MD, et al. changes in pulmonary function following image-guided stereotactic lung radiotherapy: neither lower baseline nor Post-SBRT pulmonary function are associated with worse overall survival. J Thorac Oncol. 2015 Dec;10(12):1762–1769. DOI:https://doi.org/10.1097/JTO.0000000000000670.
- Henderson M, McGarry R, Yiannoutsos C, et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.Int. J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):404–409. doi:https://doi.org/10.1016/j.ijrobp.2007.12.051
- Rancati T, Ceresoli GL, Gagliardi G, et al. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol. 2003;67:275–283.
- Kimura T, Togami T, Takashima H, et al. Radiation pneumonitis in patients with lung and mediastinal tumours: a retrospective study of risk factors focused on pulmonary emphysema. Br J Radiol. 2012;85:135–141.
- Dehing-Oberije C, De Ruysscher D, Van Baardwijk A, et al. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother Oncol. 2009;91:421–426.
- Hildebrandt MA, Komaki R, Liao Z, et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS ONE. 2010;5:e12402.
- Borghetti P, Toraci C, Imbrescia J, et al. The potential role of SPECT/CT in the clinical management of COVID-19 lung cancer patients undergoing radiotherapy. Ann Nucl Med. 2021Jul;28:1–3. DOI:https://doi.org/10.1007/s12149-021-01662-z
- HJ L Jr, Zeng J, Vesselle HJ, et al. Correlation of functional lung heterogeneity and dosimetry to radiation pneumonitis using perfusion SPECT/CT and FDG PET/CT Imaging. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1255–1264. doi:https://doi.org/10.1016/j.ijrobp.2018.05.051
- Thomas HMT, Zeng J, HJ L Jr, et al. Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy. Br J Radiol. 2019 Nov;92(1103):20190174. DOI:https://doi.org/10.1259/bjr.20190174. Epub 2019 Aug 12.
- Weller A, Dunlop A, Oxer A, et al. Spect perfusion imaging versus CT for predicting radiation injury to normal lung in lung cancer patients. Br J Radiol. 2019 Sep;92(1101):20190184. DOI:https://doi.org/10.1259/bjr.20190184.
- Hernando ML, Marks LB, Bentel GC, et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:650–659.
- Fay M, Tan A, Fisher R, et al. Dose-volume histogram analysis as predictor of radiation pneumonitis in primary lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1355–1363.
- Wang D, Shi J, Liang S, et al. Dose-volume histogram parameters for predicting radiation pneumonitis using receiver operating characteristic curve. Clin Trans Oncol. 2013;15:364–369.
- Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: american society of clinical oncology clinical practice guideline endorsement of the american society for radiation oncology evidence-based clinical practice guideline. J Clin Oncol. 2015 Jun 20;3318:2100–2105. https://doi.org/10.1200/JCO.2014.59.2360. Epub 2015 May 5.
- Graham MV, Purdy JA, Emami B, et al. Clinical dose–volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;45:323-9.
- Bradley JD, Hope A, El Naqa I, et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys. 2007;69:985–992.
- Kong FM, Wang S. Nondosimetric risk factors for radiation-induced lung toxicity. Semin Radiat Oncol. 2015;25:100–109.
- Chun SG, Hu C, Choy H, et al. Impact of Intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017 Jan;35(1):56–62. DOI:https://doi.org/10.1200/JCO.2016.69.1378.
- Koshy M, Malik R, Spiotto M, et al. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. Lung Cancer. 2017 Jun; 108 222–227. https://doi.org/10.1016/j.lungcan.2017.04.006. Epub 2017 Apr 17.
- Hu X, He W, Wen S, et al. Is IMRT superior or inferior to 3DCRT in radiotherapy for NSCLC? A meta-analysis. PLoS One. 2016 Apr 21;11(4):e0151988. doi:https://doi.org/10.1371/journal.pone.0151988
- Chan C, Lang S, Rowbottom C, et al. Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol. 2014 Nov;9(11):1598–1608. DOI:https://doi.org/10.1097/JTO.0000000000000346.
- Jegadeesh N, Liu Y, Gillespie T, et al. Evaluating Intensity-modulated radiation therapy in locally advanced non-small-cell lung cancer: results from the national cancer data base. Clin Lung Cancer. 2016 Sep;17(5):398–405. DOI:https://doi.org/10.1016/j.cllc.2016.01.007.
- Underberg RW, van Sörnsen de Koste JR, Lagerwaard FJ, et al. A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer. Radiat Oncol. 2006 Mar 31;1:8.
- Bai T, Zhu J, Yin Y, et al. How does four-dimensional computed tomography spare normal tissues in non-small cell lung cancer radiotherapy by defining internal target volume? Thorac Cancer. 2014 Nov;5(6):537–542. DOI:https://doi.org/10.1111/1759-7714.12126.
- Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev. 2017 Jun 7;6(6). DOI:https://doi.org/10.1002/14651858.CD012020.pub2. CD012020.
- Tarumi S, Yokomise H, Gotoh M, et al. Pulmonary rehabilitation during induction chemoradiotherapy for lung cancer improves pulmonary function. J Thorac Cardiovasc Surg. 2015 Feb;149(2):569–573. DOI:https://doi.org/10.1016/j.jtcvs.2014.09.123.
- Choi MG, Lee HY, Song SY, et al. The effects of simultaneous pulmonary rehabilitation during thoracic radiotherapy in the treatment of malignant diseases. Tuberc Respir Dis (Seoul). 2021 Apr;84(2):148–158. DOI:https://doi.org/10.4046/trd.2020.0135.
- Stigt JA, Uil SM, van Riesen Sjh, et al. A randomized controlled trial of postthoracotomy pulmonary rehabilitation in patients with resectable lung cancer. J Thorac Oncol. 2013 Feb;8(2):214–221. DOI:https://doi.org/10.1097/JTO.0b013e318279d52a.
- Ozturk B, Egehan I, Atavci S, et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2004;58:213–219.
- Medhora M, Gao F, Jacobs ER, et al. Radiation damage to the lung: mitigation by angiotensin-converting enzyme (ACE) inhibitors. Respirology. 2012;17:66–71.
- Takeda A, Tsurugai Y, Sanuki N, et al. Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy. J Thorac Dis. 2018 Jan;10(1):247–261. DOI:https://doi.org/10.21037/jtd.2017.12.22.
- Sabetta JR, DePetrillo P, Cipriani RJ, et al. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One. 2010 Jun 14;5(6):e11088. doi:https://doi.org/10.1371/journal.pone.0011088
- Guerini AE, Borghetti P, Filippi AR, et al. Differential diagnosis and clinical management of a case of COVID-19 in a patient with stage III lung cancer treated with radio-chemotherapy and durvalumab. Clin Lung Cancer. 2020 Nov;21(6):e547–e550. DOI:https://doi.org/10.1016/j.cllc.2020.05.027.
- Buglione M, Guerini AE, Filippi AR, et al. A Systematic review on intensity modulated radiation therapy for mediastinal hodgkin’s lymphoma. Crit Rev Oncol Hematol. 2021Aug;3:103437. DOI:https://doi.org/10.1016/j.critrevonc.2021.103437
- Armanious MA, Mohammadi H, Khodor S, et al. Cardiovascular effects of radiation therapy. Curr Probl Cancer. 2018 Jul;42(4):433–442. DOI:https://doi.org/10.1016/j.currproblcancer.2018.05.008. Epub 2018 Jun 12.
- Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–199. **A reference paper for the modern radiotherapy in locally advanced NSCLC
- Atkins KM, Rawal B, Chaunzwa TL, et al. Cardiac radiation dose, cardiac disease, and mortality in patients with lung cancer. J Am Coll Cardiol. 2019;73(23):2976–2987.
- Wang K, Eblan MJ, Deal AM, et al. Cardiac toxicity after radiotherapy for stage iii non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol. 2017;35(13):1387–1394.
- Speirs CK, DeWees TA, Rehman S, et al. Heart dose is an independent dosimetric predictor of overall survival in locally advanced non–small cell lung cancer. J Thorac Oncol. 2017 Feb;12(2):293–301. DOI:https://doi.org/10.1016/j.jtho.2016.09.134.
- Wang K, Pearlstein KA, Patchett ND, et al. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol. 2017;125(2):293–300.
- Yegya-Raman N, Wang K, Kim S, et al. Dosimetric predictors of symptomatic cardiac events after conventional-dose chemoradiation therapy for inoperable NSCLC. J Thorac Oncol. 2018;13(10):1508–1518.
- Atkins KM, Chaunzwa TL, Lamba N, et al. Association of left anterior descending coronary artery radiation dose with major adverse cardiac events and mortality in patients with non-small cell lung cancer. JAMA Oncol. 2021 Feb 1;7(2):206–219. doi:https://doi.org/10.1001/jamaoncol.2020.6332
- Zhang TW, Snir J, Boldt RG, et al. Is the importance of heart dose overstated in the treatment of non-small cell lung cancer? A systematic review of the literature. Int J Radiat Oncol Biol Phys. 2019;104(3):582–589.
- Pan L, Lei D, Wang, et al. Heart dose linked with cardiac events and overall survival in lung cancer radiotherapy: a meta-analysis. Medicine (Baltimore). 2020 Sep 18;99(38):e21964. doi:https://doi.org/10.1097/MD.0000000000021964
- Atkins KM, Bitterman DS, Chaunzwa TL, et al. Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy. Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1473–1479. doi:https://doi.org/10.1016/j.ijrobp.2021.03.005
- Duane F, Aznar MC, Bartlett F, et al. A cardiac contouring atlas for radiotherapy. Radiother Oncol. 2017 Mar;122(3):416–422. DOI:https://doi.org/10.1016/j.radonc.2017.01.008.
- Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):10–18. doi:https://doi.org/10.1016/j.ijrobp.2009.10.058
- Zhou R, Liao Z, Pan T, et al. Cardiac atlas development and validation for automatic segmentation of cardiac substructures. Radiother Oncol. 2017 Jan;122(1):66–71. DOI:https://doi.org/10.1016/j.radonc.2016.11.016.
- Atkins KM, Bitterman DS, Chaunzwa TL, et al. Statin use, heart radiation dose, and survival in locally advanced lung cancer. Pract Radiat Oncol. 2021 Jan 18;S1879-8500(21):2–3. doi:https://doi.org/10.1016/j.prro.2020.12.006
- Dess RT, Sun Y, Matuszak MM, et al. Cardiac events after radiation therapy: combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer. J Clin Oncol. 2017;35(13):1395–1402.
- Groarke JD, Nguyen PL, Nohria A, et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur Heart J. 2014 Mar;35(10):612–623. DOI:https://doi.org/10.1093/eurheartj/eht114.
- Zaborowska-Szmit M, Krzakowski M, Kowalski DM, et al. Cardiovascular complications of systemic therapy in non-small-cell lung cancer. J Clin Med. 2020 Apr 27;9(5):1268. DOI:https://doi.org/10.3390/jcm9051268.
- Varricchi G, Marone G, Mercurio V, et al. Immune checkpoint inhibitors and cardiac toxicity: an emerging issue. Curr Med Chem. 2018;25(11):1327–1339.
- McNew LK, Bowen SR, Gopan O. The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. Adv Radiat Oncol. 2017 Feb 1;2(2):192–196. DOI:https://doi.org/10.1016/j.adro.2017.01.008.
- Contreras JA, Lin AJ, Weiner A, et al. Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2018;128:498–504.
- Jin JY, Hu C, Xiao Y, et al. Higher radiation dose to immune system correlates with poorer survival in patients with stage III non-small cell lung cancer: a secondary analysis of a randomized phase III cooperative group trial (NRG Oncology RTOG0617). Int J Radiat Oncol Biol Phys. 2017;99:S151–S152.
- De Ruysscher D, Faivre-Finn C, Moeller D, et al. European organization for research and treatment of cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol. 2017 Jul;124(1):1–10. DOI:https://doi.org/10.1016/j.radonc.2017.06.003.
- Ohri N, Shen X, Dicker AP. Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst. 2013 Mar 20;105(6):387–393. DOI:https://doi.org/10.1093/jnci/djt001.
- Machtay M, Bae K, Movsas B, et al. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):425–434. doi:https://doi.org/10.1016/j.ijrobp.2010.09.004
- Bradley JD, Hu C, Komaki RR, et al. Long-Term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020 Mar 1;38(7):706–714. doi:https://doi.org/10.1200/JCO.19.01162
- Baumann M, Herrmann T, Koch R, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol. 2011 Jul;100(1):76–85. DOI:https://doi.org/10.1016/j.radonc.2011.06.031.
- Sanganalmath P, Lester JE, Bradshaw AG, et al. Continuous hyperfractionated accelerated radiotherapy (CHART) for non-small cell lung cancer (NSCLC): 7 years’ experience from nine UK Centres. Clin Oncol (R Coll Radiol). 2018 Mar;30(3):144–150. DOI:https://doi.org/10.1016/j.clon.2017.12.019.
- Mauguen A, Le Péchoux C, Saunders MI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol. 2012 Aug 1;30(22):2788–2797. doi:https://doi.org/10.1200/JCO.2012.41.6677
- Zhang W, Liu Q, Dong X, et al. A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer. J Thorac Dis. 2015 Mar;7(3):478–485. DOI:https://doi.org/10.3978/j.issn.2072-1439.2015.02.20.
- Partridge M, Ramos M, Sardaro A, et al. Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother Oncol. 2011 Apr;99(1):6–11. DOI:https://doi.org/10.1016/j.radonc.2011.02.014.
- Nix MG, Rowbottom CG, Vivekanandan S. Chemoradiotherapy of locally-advanced non-small cell lung cancer: analysis of radiation dose-response, chemotherapy and survival-limiting toxicity effects indicates a low alpha/beta ratio. Radiother Oncol. 2020Feb;143:58–65. DOI:https://doi.org/10.1016/j.radonc.2019.07.026
- Din OS, Harden SV, Hudson E, et al. Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres. Radiother Oncol. 2013 Oct;109(1):8–12. DOI:https://doi.org/10.1016/j.radonc.2013.07.014.
- Maguire J, Khan I, McMenemin R, et al. SOCCAR: a randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer. 2014 Nov;50(17):2939–2949. DOI:https://doi.org/10.1016/j.ejca.2014.07.009.
- Walraven I, van den Heuvel M, van Diessen, et al. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol. 2016 Mar;118(3):442–446. DOI:https://doi.org/10.1016/j.radonc.2016.02.011.
- Iqbal MS, Vashisht G, McMenemin R, et al. Hypofractionated concomitant chemoradiation in inoperable locally advanced non-small Cell Lung Cancer: a report on 100 patients and a systematic review. Clin Oncol (R Coll Radiol). 2019 Feb;31(2):e1–e10. DOI:https://doi.org/10.1016/j.clon.2018.10.006.
- Parisi G, Mazzola R, Ciammella P, et al. Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian association of radiation oncology. AIRO)-Lung Working Group. Radiol Med. 2019 Feb;124(2):136-144
- Parisi E, Genestreti G, Sarnelli A, et al. Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up. Radiat Oncol. 2019 Jun 24;14(1):112. doi:https://doi.org/10.1186/s13014-019-1317-x
- Urbanic JJ, Wang X, Bogart JA, et al. Phase 1 Study of accelerated hypofractionated radiation therapy with concurrent chemotherapy for stage iii non-small cell lung cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):177–185. doi:https://doi.org/10.1016/j.ijrobp.2018.01.046
- Glinski K, Socha J, Wasilewska-Tesluk E, et al. Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: a phase I/II study. Radiother Oncol. 2020Jul;148:174–180. DOI:https://doi.org/10.1016/j.radonc.2020.04.033
- Guckenberger M, Belka C, Bezjak A, et al. Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement. Radiother Oncol. 2020May;146:223–229. DOI:https://doi.org/10.1016/j.radonc.2020.04.001
- Zhao Q, Chen G, Ye L, et al. Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC. Radiat Oncol. 2019 May 27;14(1):86. doi:https://doi.org/10.1186/s13014-019-1287-z
- Hurria A, Dale W, AL MMET. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014 Aug 20;32( 24):2587–2594. ASCO 2014: Chicago, Illinois, USA, doi: https://doi.org/10.1200/JCO.2013.55.0418.
- Miller ED, Fisher JL, Haglund KE, et al. Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiat Oncol. 2018 Oct 5;13(1):196. doi:https://doi.org/10.1186/s13014-018-1142-7
- Driessen EJM, Bootsma GP, Hendriks LEL, et al. Stage III Non-Small Cell Lung Cancer in the elderly: patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. Radiother Oncol. 2016 Oct;121(1):26–31. DOI:https://doi.org/10.1016/j.radonc.2016.07.025.
- Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–M157.
- Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62:722–727.
- Jeremic B, Shibamoto Y, Milicic B, et al. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):343–348. doi:https://doi.org/10.1016/s0360-3016(99)00006-1
- Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012 Jul;13(7):671–678. DOI:https://doi.org/10.1016/S1470-2045(12)70139-0.
- Bayman N, Alam N, Faivre-Finn C. Radiotherapy for lung cancer in the elderly. Lung Cancer. 2010 May;68(2):129–136. DOI:https://doi.org/10.1016/j.lungcan.2009.12.004.
- WJ C Jr, Paulus R, Langer CJ, et al. Sequential vs concurrent chemoradiation for stage III non–small cell lung cancer: randomized phase III Trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452–1460. doi:https://doi.org/10.1093/jnci/djr325
- Miller ED, Fisher JL, Haglund KE, et al. The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage iii non-small cell lung cancer. J Thorac Oncol. 2018 Mar;13(3):426–435. DOI:https://doi.org/10.1016/j.jtho.2017.11.135.
- Townsley CA, Chan KK, Pond GR, et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 2006 Feb 8;6:34. DOI:https://doi.org/10.1186/1471-2407-6-34
- Arulananda S, Mitchell P. Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S388–S392. DOI:https://doi.org/10.21037/tlcr.2018.08.12.
- Puts MT, Hardt J, Monette J, et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst. 2012 Aug 8;104(15):1133–1163. doi:https://doi.org/10.1093/jnci/djs285
- Kenis C, Bron D, Libert Y, et al. Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study. Ann Oncol. 2013 May;24(5):1306–1312. DOI:https://doi.org/10.1093/annonc/mds619.
- Cuccia F, Mortellaro G, Mazzola R, et al. Prognostic value of two geriatric screening tools in a cohort of older patients with early stage Non-Small Cell Lung Cancer treated with hypofractionated stereotactic radiotherapy. J Geriatr Oncol. 2020 Apr;11(3):475–481. DOI:https://doi.org/10.1016/j.jgo.2019.05.002.
- Agemi Y, Shimokawa T, Sasaki J, et al. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study. PLoS One. 2019 Jan 17;14(1):e0210499. doi:https://doi.org/10.1371/journal.pone.0210499
- Johnstone DW, Byhardt RW, Ettinger D, et al., Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. 2002; Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 54:365–369. https://doi.org/10.1016/S0360-3016(02)02943-7
- van Meerbeeck JP, Kramer GW, Van Schil PE, et al. European organisation for research and treatment of cancer-lung cancer group randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99:442–450.
- Sorensen JB, Ravn J, Pilegaard HK, et al. Surgery for NSCLC stages T1-3N2M0 having preoperative pathologically verified N2 involvement: a prospective randomized multinational phase III trial by the Nordic Thoracic Oncology Group. J Clin Oncol. 2013;31(7504). DOI:https://doi.org/10.1200/jco.2013.31.15_suppl.7504.
- Shepherd FA, Johnston MR, Payne D, et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a national cancer institute of canada clinical trials group study. Br J Cancer. 1998;78:683–685.
- Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–386.
- Eberhardt WE, Pöttgen C, Gauler TC, et al. Phase III Study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE. J Clin Oncol. 2015;33:4194–4201.
- Pöttgen C, Eberhardt W, Stamatis G, et al. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017 Jun 20;8(25):41670–41678. doi:https://doi.org/10.18632/oncotarget.16471
- Glatzer M, Leskow P, Caparrotti F, et al. Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists. Transl Lung Cancer Res. 2021 Apr;10(4):1960–1968. DOI:https://doi.org/10.21037/tlcr-20-1210.
- Putora PM, Leskow P, McDonald F, et al. International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Res. 2020 Feb 17;6(1):00159–2019. doi:https://doi.org/10.1183/23120541.00159-2019
- Veeramachaneni NK, Feins RH, Stephenson BJ, et al. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012Sep;943:922–926. https://doi.org/10.1016/j.athoracsur.2012.04.087 discussion 926-8
- Huber RM, De Ruysscher D, Hoffmann H, et al. Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. Eur Respir Rev. 2019 Jul 8 28(152):190024. https://doi.org/10.1183/16000617.0024-2019
- Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv1–iv21. ESMO Guidelines Committee. DOI:https://doi.org/10.1093/annonc/mdx222.
- Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase iii trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2016 Mar 20;34(9):953–962. doi:https://doi.org/10.1200/JCO.2015.64.8824
- Santana-Davila R, Devisetty K, Szabo A, et al. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol. 2015 Feb 20;33(6):567–574. doi:https://doi.org/10.1200/JCO.2014.56.2587
- Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the hoosier oncology group and U.S. Oncology. J Clin Oncol 2008 Dec 10, 26: (35) 5755–5760. https://doi.org/10.1200/JCO.2008.17.7840
- Ahn JS, Ahn YC, Kim J-H. Kim J et al.multinational randomized phase iii trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015 Aug 20;33(24):2660–2666. DOI:https://doi.org/10.1200/JCO.2014.60.0130.
- Faivre-Finn C, Vicente D, Kurata T, et al. Four-Year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC Trial. J Thorac Oncol. 2021 May;16(5):860–867. DOI:https://doi.org/10.1016/j.jtho.2020.12.015.
- Passiglia F, Leone G, Olmetto E, et al. Immune-checkpoint inhibition in stage III unresectable NSCLC: challenges and opportunities in the post-PACIFIC era. Lung Cancer. 2021;157:85–91.
- Guerini AE, Filippi AR, Tucci A, et al. ‘Le Roi est mort, vive le Roi’: new roles of radiotherapy in the treatment of lymphomas in combination with immunotherapy. clinical lymphoma Myeloma and Leuk. 2022 Feb;22(2):e135-e148. doi: https://doi.org/10.1016/j.clml.2021.09.005. Epub 2021 Sep 10. PMID: 34728169.
- Kordbacheh T, Honeychurch J, Blackhall F, et al. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. Ann Oncol. 2018 Feb 1;29(2):301–310. doi:https://doi.org/10.1093/annonc/mdx790
- Ren XC, Liu YE, Li J, et al. Progress in image-guided radiotherapy for the treatment of non-small cell lung cancer. World J Radiol. 2019 Mar 28;11(3):46–54. DOI:https://doi.org/10.4329/wjr.v11.i3.46.
- Ahmed N, Venkataraman S, Johnson K, et al. Does motion assessment with 4-dimensional computed tomographic imaging for non-small cell lung cancer radiotherapy improve target volume coverage? Clin Med Insights Oncol. 2017 Mar 14;11:1179554917698461. DOI:https://doi.org/10.1177/1179554917698461
- Giaj-Levra N, Borghetti P, Bruni A, et al. Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Rev Anticancer Ther. 2020 May;20(5):387–402. DOI:https://doi.org/10.1080/14737140.2020.1760094.